Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.

Facchinetti F, Loriot Y, Brayé F, Vasseur D, Bahleda R, Bigot L, Barbé R, Nobre C, Combarel D, Michiels S, Italiano A, Smolenschi C, Tselikas L, Scoazec JY, Ponce-Aix S, Besse B, André F, Olaussen KA, Hollebecque A, Friboulet L.

Open source

DOI: 10.1158/1078-0432.ccr-24-1834
Published: 2024-11-01
Container: Clin Cancer Res
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-24-1834,
  title = {Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.},
  author = {Facchinetti F and  Loriot Y and  Brayé F and  Vasseur D and  Bahleda R and  Bigot L and  Barbé R and  Nobre C and  Combarel D and  Michiels S and  Italiano A and  Smolenschi C and  Tselikas L and  Scoazec JY and  Ponce-Aix S and  Besse B and  André F and  Olaussen KA and  Hollebecque A and  Friboulet L.},
  year = {2024},
  journal = {Clin Cancer Res},
  doi = {10.1158/1078-0432.ccr-24-1834},
  url = {https://doi.org/10.1158/1078-0432.ccr-24-1834}
}

RIS

TY  - JOUR
TI  - Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.
AU  - Facchinetti F
AU  -  Loriot Y
AU  -  Brayé F
AU  -  Vasseur D
AU  -  Bahleda R
AU  -  Bigot L
AU  -  Barbé R
AU  -  Nobre C
AU  -  Combarel D
AU  -  Michiels S
AU  -  Italiano A
AU  -  Smolenschi C
AU  -  Tselikas L
AU  -  Scoazec JY
AU  -  Ponce-Aix S
AU  -  Besse B
AU  -  André F
AU  -  Olaussen KA
AU  -  Hollebecque A
AU  -  Friboulet L.
PY  - 2024
JO  - Clin Cancer Res
DO  - 10.1158/1078-0432.ccr-24-1834
UR  - https://doi.org/10.1158/1078-0432.ccr-24-1834
ER  -

APA

F, F., Y, L., F, B., D, V., R, B., L, B., R, B., C, N., D, C., S, M., A, I., C, S., L, T., JY, S., S, P., B, B., F, A., KA, O., A, H., & L., F. (2024). Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.. Clin Cancer Res. https://doi.org/10.1158/1078-0432.ccr-24-1834

Source records

europe-pmc · retrieved 2026-09-26T06:17:59.056Z
hal · retrieved 2026-09-26T06:17:59.067Z